Ionis Pharmaceuticals are leaders in antisense technology and have developed an array of antisense oligonucleotides (ASO) targeting translation of complement proteins, including CFB; ASO-targeting of CFB reduced levels of circulating CFB (to < 20% normal levels) and improved survival, proteinuria and renal pathology in murine lupus nephritis [77]. Here, CFB is linked to lupus nephritis.